# A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

> **NCT05518045** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **LaNova Medicines Limited** · enrollment: 392 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-108
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05518045
- **Lead sponsor:** LaNova Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518045, "A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05518045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*